Literature DB >> 19787848

Validating the EQ-5D with time trade off for the German population.

W Greiner1, C Claes, J J V Busschbach, J-M Graf von der Schulenburg.   

Abstract

The aim of this survey study was to derive the societal values of the general public for the EuroQol EQ-5D. Using the same protocol as previously used in the United Kingdom, we compared the German values with the British. In face-to-face interviews a sample of 339 individuals in northern Germany valued 15 different health states from a sample of 36 states. Values were derived using the York MVH protocol for time trade-off (TTO) and a visual analogue scale (VAS). Values for all 243 health states of the EQ-5D were estimated by a regression model. The VAS values revealed close a resemblance to the British VAS results. German TTO values were higher than the British. This was especially the case for the worse health states. The results suggest that the TTO values are more related to national variables than values derived by VAS. The use of the TTO values of this investigation makes it possible to anticipate these cultural differences in studies carried out in Germany.

Mesh:

Year:  2005        PMID: 19787848     DOI: 10.1007/s10198-004-0264-z

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  133 in total

1.  The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries.

Authors:  Raymond Oppong; Billingsley Kaambwa; Jacqueline Nuttall; Kerenza Hood; Richard D Smith; Joanna Coast
Journal:  Eur J Health Econ       Date:  2011-11-05

2.  Does the EQ-5D reflect lost earnings?

Authors:  Carl Tilling; Marieke Krol; Aki Tsuchiya; John Brazier; Job van Exel; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2012-01       Impact factor: 4.981

3.  Do Portuguese and UK health state values differ across valuation methods?

Authors:  Lara N Ferreira; Pedro L Ferreira; Donna Rowen; John E Brazier
Journal:  Qual Life Res       Date:  2011-05       Impact factor: 4.147

4.  Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer.

Authors:  K Lien; V C Tam; Y J Ko; N Mittmann; M C Cheung; K K W Chan
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

5.  The valuation of the EQ-5D in Portugal.

Authors:  Lara N Ferreira; Pedro L Ferreira; Luis N Pereira; Mark Oppe
Journal:  Qual Life Res       Date:  2013-06-08       Impact factor: 4.147

6.  Utilities of the EQ-5D: transferable or not?

Authors:  Saskia Knies; Silvia M A A Evers; Math J J M Candel; Johan L Severens; André J H A Ament
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 7.  Experience-Based Values: A Framework for Classifying Different Types of Experience in Health Valuation Research.

Authors:  Patricia Cubi-Molla; Koonal Shah; Kristina Burström
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

8.  Health economic burden of patients with restless legs syndrome in a German ambulatory setting.

Authors:  Richard Dodel; Svenja Happe; Ines Peglau; Geert Mayer; Jürgen Wasem; Jens-Peter Reese; Guido Giani; Max Geraedts; Claudia Trenkwalder; Wolfgang H Oertel; Karin Stiasny-Kolster
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

9.  Tailored care for somatoform vertigo/dizziness: study protocol for a randomised controlled trial evaluating integrative group psychotherapy.

Authors:  Claas Lahmann; P Henningsen; M Dieterich; K Radziej; G Schmid
Journal:  J Neurol       Date:  2015-05-23       Impact factor: 4.849

10.  Impact of restless legs syndrome in patients with inflammatory bowel disease on sleep, fatigue, and quality of life.

Authors:  Katharina A Schindlbeck; Janek Becker; Felix Berger; Arne Mehl; Charlotte Rewitzer; Sarah Geffe; Peter M Koch; Jan C Preiß; Britta Siegmund; Jochen Maul; Frank Marzinzik
Journal:  Int J Colorectal Dis       Date:  2016-10-18       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.